Wellgistics Health Inc (WGRX)
NASDAQHealth CareMedical - DistributionSnapshot 2026-09-04
$3.59+15.06%
Close 2026-07-28 · 1-day change
NASDAQHealth CareMedical - DistributionSnapshot 2026-09-04
QuarterlyIQ Insights · WGRX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Build a unified blockchain-based data fabric integrating pharmacy, manufacturers, and patient care for healthcare efficiency and trust.
Newly stated in 2026-Q1. Management articulated a strategic focus on vertical integration and blockchain infrastructure as the foundation for future healthcare efficiency. Financials show revenue of $1.56M in 2026-Q1 and $1.78M in 2026-Q2, indicating early-stage growth consistent with this strategic direction but no direct financial impact yet. The trajectory is nascent with foundational investments underway.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We are building the data layer that the rest of the industry will eventually need to plug into, integrating blockchain and AI platforms.”
Meet or exceed the guided revenue target of $1.775 million for the second quarter of 2026.
Stated in 2 of last 2 quarters. The company guided to $1.775 million revenue for 2026-Q2 and reported $1.78 million, slightly exceeding guidance. Revenue grew from $1.56 million in 2026-Q1 to $1.78 million in 2026-Q2, showing delivery on this target.
“Revenue reported at $1.78 million, aligning with prior guidance of $1.775 million for the quarter.”
“Guidance provided expecting $1.775 million revenue for Q2 2026.”
Respond to Nasdaq notification regarding stockholders' equity deficiency and work to maintain listing compliance.
Newly stated in 2026-Q2. The company received a Nasdaq notice for non-compliance due to stockholders' equity below the $2.5 million minimum. Financials show continued net losses and negative operating income, indicating challenges in restoring compliance. The trajectory is concerning with limited progress toward equity improvement.
“Received letter from Nasdaq indicating stockholders' equity did not satisfy continued listing requirements.”
Finalize acquisitions and partnerships including Datavault AI, Tollo Health, and Kare Pharmtech to enhance platform and patient engagement.
Newly stated in 2026-Q1. Management disclosed multiple strategic acquisitions and partnerships to expand capabilities and vertical integration. Financials show early-stage revenue growth but continued losses, indicating foundational work underway with limited immediate financial impact. The trajectory is early with foundational progress.
“Announced acquisitions and partnerships to build integrated healthcare platform and patient engagement.”
Secure new capital through convertible promissory notes and restructure debt to support operations and growth.
Newly stated in 2026-Q2. The company raised $21.1 million through convertible promissory notes and warrants to support operations. Despite this capital raise, operating income remains negative at -$7.3 million in 2026-Q2, indicating ongoing cash burn. The trajectory shows capital infusion but continued operational losses.
“Entered into agreement to issue $21.1 million in convertible notes and warrants to raise capital.”
Over the trailing year it converted 0.08x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
63 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.